Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma

Overview

Journal Clin Lymphoma Myeloma Leuk

Publisher Elsevier

Specialty Oncology

Date 2014 Mar 22

PMID 24650973

Citations 48

Authors

Jason R Westin

Affiliations

Soon will be listed here.

Abstract

The phosphatidylinositol-3-kinase (PI3K) pathway is well known to regulate a wide variety of essential cellular functions, including glucose metabolism, translational regulation of protein synthesis, cell proliferation, apoptosis, and survival. Aberrations in the PI3K pathway are among the most frequently observed in cancer, and include amplifications, rearrangements, mutations, and loss of regulators. As a net result of these anomalies, the PI3K pathway is activated in many malignancies, including in Hodgkin and non-Hodgkin lymphomas, and yields a competitive growth and survival advantage, increased metastatic ability, and resistance to conventional therapy. Numerous inhibitors targeting various nodes in the PI3K pathway are undergoing clinical development, and their current status in lymphoma will be the focus of this review.

Citing Articles

Brigatinib can inhibit proliferation and induce apoptosis of human immortalized keratinocyte cells.

Yang Q, Zhao D, Ju L, Cao P, Wei J, Liu Z Front Pharmacol. 2025; 16:1524277.

PMID: 40041486 PMC: 11876137. DOI: 10.3389/fphar.2025.1524277.

Molecular Mechanisms and Therapeutic Prospects of Immunotherapy and Targeted Therapy in Primary Central Nervous System Lymphoma.

Zhong L, Lu A, Lu X, Liu X, Cao L, Zhu S Technol Cancer Res Treat. 2025; 24:15330338251319394.

PMID: 39912261 PMC: 11800258. DOI: 10.1177/15330338251319394.

Advancements in B-Cell Non-Hodgkin's Lymphoma: From Signaling Pathways to Targeted Therapies.

Alfaifi A, Bahashwan S, Alsaadi M, Ageel A, Ahmed H, Fatima K Adv Hematol. 2024; 2024:5948170.

PMID: 39563886 PMC: 11576080. DOI: 10.1155/2024/5948170.

LLLT accelerates experimental wound healing under microgravity conditions via PI3K/AKT-CCR2 signal axis.

Ye R, He Y, Ni W, Zhang Y, Zhu Y, Cao M Front Bioeng Biotechnol. 2024; 12:1387474.

PMID: 39193227 PMC: 11347831. DOI: 10.3389/fbioe.2024.1387474.

Multiple omics levels of chronic lymphocytic leukemia.

Turk A, ceh E, Calin G, Kunej T Cell Death Discov. 2024; 10(1):293.

PMID: 38906881 PMC: 11192936. DOI: 10.1038/s41420-024-02068-2.

References

Zent C, LaPlant B, Johnston P, Call T, Habermann T, Micallef I . The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer. 2010; 116(9):2201-7. PMC: 2861142. DOI: 10.1002/cncr.25005. View

Wlodarski P, Kasprzycka M, Liu X, Marzec M, Robertson E, Slupianek A . Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum. Cancer Res. 2005; 65(17):7800-8. DOI: 10.1158/0008-5472.CAN-04-4180. View

Brachmann S, Ueki K, Engelman J, Kahn R, Cantley L . Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. Mol Cell Biol. 2005; 25(5):1596-607. PMC: 549361. DOI: 10.1128/MCB.25.5.1596-1607.2005. View

Kondapaka S, Singh S, Dasmahapatra G, Sausville E, Roy K . Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther. 2003; 2(11):1093-103. View

Oki Y, Buglio D, Fanale M, Fayad L, Copeland A, Romaguera J . Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res. 2013; 19(24):6882-90. PMC: 4409814. DOI: 10.1158/1078-0432.CCR-13-1906. View

Jackson S, Schoenwaelder S, Goncalves I, Nesbitt W, Yap C, Wright C . PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med. 2005; 11(5):507-14. DOI: 10.1038/nm1232. View

Heron-Milhavet L, Franckhauser C, Rana V, Berthenet C, Fisher D, Hemmings B . Only Akt1 is required for proliferation, while Akt2 promotes cell cycle exit through p21 binding. Mol Cell Biol. 2006; 26(22):8267-80. PMC: 1636765. DOI: 10.1128/MCB.00201-06. View

Bi L, Okabe I, Bernard D, Wynshaw-Boris A, Nussbaum R . Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J Biol Chem. 1999; 274(16):10963-8. DOI: 10.1074/jbc.274.16.10963. View

Baohua Y, Xiaoyan Z, Tiecheng Z, Tao Q, Daren S . Mutations of the PIK3CA gene in diffuse large B cell lymphoma. Diagn Mol Pathol. 2008; 17(3):159-65. DOI: 10.1097/PDM.0b013e31815d0588. View

10.

Sansal I, Sellers W . The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol. 2004; 22(14):2954-63. DOI: 10.1200/JCO.2004.02.141. View

11.

Cai S, Tee A, Short J, Bergeron J, Kim J, Shen J . Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J Cell Biol. 2006; 173(2):279-89. PMC: 2063818. DOI: 10.1083/jcb.200507119. View

12.

Guillermet-Guibert J, Bjorklof K, Salpekar A, Gonella C, Ramadani F, Bilancio A . The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci U S A. 2008; 105(24):8292-7. PMC: 2448830. DOI: 10.1073/pnas.0707761105. View

13.

Lemoine M, Derenzini E, Buglio D, Medeiros L, Davis R, Zhang J . The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood. 2012; 119(17):4017-25. PMC: 3350366. DOI: 10.1182/blood-2011-01-331421. View

14.

Geva-Zatorsky N, Dekel E, Cohen A, Danon T, Cohen L, Alon U . Protein dynamics in drug combinations: a linear superposition of individual-drug responses. Cell. 2010; 140(5):643-51. DOI: 10.1016/j.cell.2010.02.011. View

15.

Benson R, Hostager B, Bishop G . Rapid CD40-mediated rescue from CD95-induced apoptosis requires TNFR-associated factor-6 and PI3K. Eur J Immunol. 2006; 36(9):2535-43. DOI: 10.1002/eji.200535483. View

16.

Swat W, Montgrain V, Doggett T, Douangpanya J, Puri K, Vermi W . Essential role of PI3Kdelta and PI3Kgamma in thymocyte survival. Blood. 2005; 107(6):2415-22. PMC: 1895732. DOI: 10.1182/blood-2005-08-3300. View

17.

Oudit G, Sun H, Kerfant B, A Crackower M, Penninger J, Backx P . The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol. 2004; 37(2):449-71. DOI: 10.1016/j.yjmcc.2004.05.015. View

18.

Engelman J . Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009; 9(8):550-62. DOI: 10.1038/nrc2664. View

19.

Psyrri A, Papageorgiou S, Liakata E, Scorilas A, Rontogianni D, Kontos C . Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res. 2009; 15(18):5724-32. DOI: 10.1158/1078-0432.CCR-08-3215. View

20.

Witzig T, Geyer S, Ghobrial I, Inwards D, Fonseca R, Kurtin P . Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005; 23(23):5347-56. DOI: 10.1200/JCO.2005.13.466. View